@OncEd Presents Dr. Linh Nguyen – The Basic Premise of Immuno-Oncology – Best Of Immuno-Oncology
Author: Editor
@OncEd Presents Panel Discussion: Workforce Planning in Oncology Across Canada – CAMO 2015
@OncEd Presents Dr. Jean Latreille – HR Planning in Oncology: Quebec – CAMO 2015
@OncEd Presents Dr. Leonard Kaizer – HR Planning in Oncology: Ontario – CAMO 2015
@OncEd Presents Dr. Chris Lee – HR Planning in Oncology: British Columbia – CAMO 2015
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Annie Young, SRN, PhD, Professor of Nursing, University of Warwick, Coventry, UK, discusses the clinical significance of chemotherapy-induced nausea and vomiting, which continues to greatly impact the quality of life of patients, and the role of oncology nurses in the management and education of patients undergoing potentially emetogenic therapy. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Ali Hodge, Advanced Nurse Practitioner for Acute Oncology at The Royal Marsden NHS Foundation Trust, London, UK, discusses an audit that was designed to evaluate the Acute Oncology Service nursing role across the London Cancer Alliance, which is a collaboration of 17 healthcare provider organisations in London, as well as determining their professional development needs. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
From our Ask the Expert series, MPN expert Dr. Bart Scott from Seattle Cancer Care Alliance and the Fred Hutchinson Cancer Research Center responds to Patient Power community member Amandas question, Is there any research on pregnancy and essential thrombocythemia (ET)? What are my risks? Dr. Scott discusses both historical and anecdotal data, including safe treatments. Dr. Scott cautions patients, however, to be sure to consult an MPN expert both before and during pregnancy. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
From our Ask the Expert series, MPN expert Dr. Jamile Shammo, with Rush University Medical Center in Chicago, answers a question from Jane, What does it mean if you are JAK+ or CALR+, and how does it affect my treatment or prognosis? Dr. Shammo compares and contrasts these two mutations, offering insight based on clinical studies and registry data. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Martin Wiseman, MD talks about how the environment we live in determines the patterns of cancer across the world. There is now an increasingly large volume of data that supports that nutritional factors, not just diet but obesity and physical activity, that determine the body’s ability to fight cancer. After smoking, obesity and physical activity are the most important factors that can be used to prevent cancer.
@OncEd Presents Dr. Allan Covens – BRCA mutations in ovarian cancer
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the results of the Pomi-T clinical trial. The study focused on the effects of Pomi-T on prostate-specific antigen (PSA) levels in prostate cancer patients. He highlights the main results, such as the reduction of PSA levels, and other important factors that should be considered when taking food supplements.
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses non-medicinal strategies to help cancer patients cope with cancer therapy side-effects. Prof. Robert Thomas suggests changes in lifestyle, such as daily light exercise and a healthy and balanced diet.
Robert Thomas, MbChb, MRCP, MD, FRCR, discusses the importance of having a healthy diet for cancer patients. Prof. Robert Thomas suggests that cancer patients and the general community, should increase the intake of fruit and vegetables, rich in polyphenols. he then goes on to discuss the results of a double-blind, randomised clinical trial (Pomi-T), where the intake of whole-food supplements rich in polyphenols, showed to reduce the levels of prostate-specific antigen (PSA) and tumour size.
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Margaret Oakes, Specialist Counselling Psychologist at Berkshire Healthcare NHS Foundation Trust, Bracknell, UK, and Kevin Johnson, Physical Activity Lead at Macmillan Cancer Support, London, UK, discuss the role of physical activity for people living with and beyond cancer and the rationale for psychological skills training for Physical Activity Specialists to improve the management of psychological distress associated with cancer and cancer treatment. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Does the development of resistant clones in multiple myeloma affect long-term treatment?
To what extent are you able to achieve long-term treatment goals in your patients with multiple myeloma?
Are there practical considerations for long-term treatment of multiple myeloma?
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michael Mawhinney, doctoral research student, Oxford Brookes University, Oxford, UK, discusses the role of healthcare professionals in addressing cancer patients’ sexuality needs and the role of assessment models, such as BETTER (Bring up sexuality; Explain role of sexuality in quality of life; Tell about and facilitate resources; Timing critical; Educate patient and partner; Record in health record), for raising sexual issues. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Leading researcher Dr. Kanti Rai has devoted his career to understanding and classifying CLL. After Dr. Rais return from the iwCLL conference, Patient Power founder Andrew Schorr visited with Dr. Rai to learn more about progress in CLL biology and how it could positively impact treatment options. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
From our latest Ask the Expert segment with MPN expert Dr. Bart Scott from Seattle Cancer Care Alliance (SCCA), he answers viewer Verns question, What is the DIPSS scoring system, and how is it used in the monitoring of MPNs? Dr. Scott explains risk scores associated with survival and how that affects choices for treatment. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Michelle Taylor, Clinical Nurse Specialist, of The Great Western Hospital, Swindon, and Jasmine Hebden, Clinical Nurse Specialist, of The Great Western Hospital, Swindon, UK, discuss the introduction of new patient-focused initiatives designed to address patients unmet needs at the end of treatment in haemato-oncology, including combining interventions such as holistic-needs assessment and support-events provision. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Debbie Gillen, of The Christie NHS Foundation Trust, Manchester, UK, discusses an acute oncology education campaign that was designed to provide acute oncology education to community and primary care teams, and thereby improve the standards of awareness and support for patients outside of the hospital setting. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Lisa Wells, Macmillan Lung Cancer Clinical Nurse Specialist, of Northampton General, Hospital NHS Trust, Northampton, UK, discusses a new lung cancer pathway project, which was designed to improve the quality of treatment and care patients receive through approaches that address the individual patient’s needs. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Andrew Turner, discusses a qualitative study of the self-management needs of men that have survived prostate and testicular cancer for the development of the web-based, self-management programme, iHOPE. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, Hilary Glen, MbChB, MSc, PhD, FRCP, of the Beatson West of Scotland Cancer Centre, Glasgow, UK, explains the clinical impact of emerging treatments, including abiraterone acetate and enzalutamide in both post-chemotherapy and pre-chemotherapy settings, on the care and quality of life of patients with metastatic castration-resistant prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the United Kingdom Oncology Nursing Society (UKONS) Annual Conference 2015, which attracts cancer nurses from around the United Kingdom and beyond, Catherine Oakley, PhD, UKONS President 20142016, and Chemotherapy Nurse Consultant at Guy’s and St Thomas’ NHS Foundation Trust, London, UK, explains the theme of the conference, Patient Safety, and the four subsidiary topics, Haemato-Oncology Nursing, Early Diagnosis and Treatment, Supporting Cancer Nurses and Initiatives in the Treatment and Care of People with Cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, explains that genetic differences between primary and metastatic breast cancer may have important clinical implications, including for the identification of biomarkers for disease progression. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Riccardo A. Audisio, MD, FRCS, of the University of Liverpool, St. Helens Teaching Hospital, St. Helens, UK, explains that nutrition has an important role in the treatment of cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Thomas Powles, MBBS, MRCP, MD, of Barts and The London School of Medicine and Dentistry, London, UK, discusses the results of clinical trials reported at the European Cancer Congress (ECC) 2015 in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Can MPN patients develop biological markers that influence their current therapies? Yes, says MPN expert Dr. Srdan Verstovsek from The University of Texas MD Anderson Cancer Center. Dr. Verstovsek discusses genetic mutations and drug resistance and what researchers are doing to stay ahead. He remains optimistic for the future as clinical trials continue to indicate increased benefits to the MPN patient population. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
How has the field of MPNs expanded in the last 10 years? Meet MPN expert Dr. Laura Michaelis, Clinician and Clinical Researcher at Medical College of Wisconsin. She sat down with Andrew to discuss the evolving landscape of MPNs and new scientific advantages that have her and other researchers excited. Using the analogy of a garden and weeds, Dr. Michaelis walks us through genetic aberrations, JAK-STAT pathway, driver mutations, and precision medicine, ending with the advent of social medias role in accelerating communication in the field of MPNs. Listen as she comments on all this progression as eventually curing people,…
Fresh from the iwCLL, CLL expert Dr. William Plunkett, Professor in the Department of Experimental Therapeutics at The University of Texas MD Anderson Cancer Center shares the latest news on CLL therapeutics with Andrew. Dr. Plunkett is on the cutting edge of biological therapy and speaks confidently of the progression of CLL treatments. Listen as he states, The future is bright for development ofdemonstrably curative CLL therapies. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Can patient care be coordinated regardless of what country you live in? When should an MPN patient start seeking expert care? MPN expert Dr. Bart Scott, Director of Hematology and Hematologic Malignancies at Seattle Cancer Care Alliance, answers these questions. Dr. Scott also discusses when an MPN patient may require changes to their treatment and what those options are, including clinical trials. Listen as Dr. Scott explains why this is a hopeful time for MPN patients. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ |…
At the European Cancer Congress (ECC) 2015, David Ross Camidge, MD, PhD, of the University of Colorado Cancer Center, Aurora, CO, explains that strategies to manage progression in patients with non-small cell lung cancer (NSCLC) should be tailored to individual patients, as there may be a need to address pharmacologic issues or the molecular emergence of new resistant clones. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study, which was designed to evaluate the prognostic and predictive value of HER2-status of circulating tumour cells in patients with metastatic breast cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Toni Choueiri, MD of the Dana-Farber Cancer Institute welcomes viewers to the 14th International Kidney Cancer Symposium 2015
Toni Choueiri, MD of the Dana-Farber Cancer Institute How Does the Axitinib Plus Pembrolizumab study impact future research?
Toni Choueiri, MD of the Dana-Farber Cancer Institute discusses the Phase Ib Dose-Finding Study of Axitinib Plus Pembrolizumab in Treatment-Naïve PatientsWith Advanced Renal Cell Carcinoma
Michael Bassetti MD PhD of the University of Wisconsin Madison discusses the next steps Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer what are the next steps?
Michael Bassetti MD PhD of University of Wisconsin Madison discusses What’s the Impact to Physicians Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer
Michael Bassetti MD PhD of the University of Wisconsin Madison discusses Stereotactic Body Radiotherapy (SBRT) for Kidney Cancer an Overview
Dr. Greco speaks about the usage of CancerTYPE ID to obtain a single diagnosis in patient with Cancer of Unknown Primary or CUP. For more information, visit http://www.cancertypeid.com
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Giampaolo Bianchini, MD, of the San Raffaele Scientific Institute, Milan, Italy, explains the impact of the Oncotype DX® Breast Cancer Assay, a multigene assay that stratifies patients into risk groups that are associated with distant recurrence and response to adjuvant chemotherapy, on treatment decisions for patients with early stage breast cancer. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a study that was designed to determine whether seropositivity to a panel of tumour antigens was associated with a risk of relapse in patients with stage II and III melanoma. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Maria De Santis, MD, of the University of Warwick, Warwick, UK, discusses the initial results of ASPIRE-PCa, a prospective, global observational study that was designed to describe patterns of care and outcomes for men with late-stage prostate cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Giuseppe Curigliano, MD, PhD, of Istituto Europeo di Oncologia, Milan, Italy, discusses molecular subgroups of triple-negative breast cancer that may have potential to be exploited for clinical trial development of new therapies, including enzalutamide, an androgen receptor signalling inhibitor; and pembrolizumab, an anti-PD-1 monoclonal antibody. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, describes the European School of Oncology-organised multidisciplinary Task Force, which focuses on reviewing access to innovation in all fields of oncology. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Laurence Albiges, MD, of Institut Gustave Roussy, Villejuif, France, discusses the results of clinical trials reported in patients with previously treated renal cell carcinoma: CheckMate 025, a phase 3 clinical trial of nivolumab versus everolimus; and METEOR, a phase 3 clinical trial of cabozantinib versus everolimus. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
At the European Cancer Congress (ECC) 2015, Johan Vansteenkiste, MD, PhD, of KU Leuven, Leuven, Belgium, discusses the primary analyses of efficacy, safety and predictive biomarkers from POPLAR, a randomised phase 2 clinical trial of atezolizumab monotherapy versus docetaxel in patients with second- or third-line non-small cell lung cancer. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews